Eluxadoline

This article needs additional citations for verification. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed. Find sources: "Eluxadoline" – news · newspapers · books · scholar · JSTOR (June 2015) (Learn how and when to remove this message)

Eluxadoline

Clinical data
Pronunciation	Viberzi (/vaɪˈbɜːrzi/ vy-BUR-zee
Trade names	Viberzi, Truberzi
Other names	JNJ-27018966
Routes of administration	By mouth
ATC code	A07DA06 (WHO)
Legal status
Legal status	CA: ℞-only[1] US: Schedule IV[2]
Pharmacokinetic data
Protein binding	81%
Elimination half-life	3.7–6 hours
Excretion	82.2% (feces), <1% (urine)[2]
Identifiers
IUPAC name 5-({[(2S)-2-amino-3-(4-carbamoyl-2,6-dimethylphenyl)propanoyl] [(1S)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino}methyl)-2-methoxybenzoic acid
CAS Number	864821-90-9
PubChem CID	11250029
IUPHAR/BPS	7691
DrugBank	DB09272
ChemSpider	9425062
UNII	45TPJ4MBQ1
KEGG	D10403
CompTox Dashboard (EPA)	DTXSID70235589
Chemical and physical data
Formula	C32H35N5O5
Molar mass	569.662 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC1=CC(=CC(=C1CC(C(=O)N(CC2=CC(=C(C=C2)OC)C(=O)O)C(C)C3=NC=C(N3)C4=CC=CC=C4)N)C)C(=O)N
InChI InChI=1S/C32H35N5O5/c1-18-12-23(29(34)38)13-19(2)24(18)15-26(33)31(39)37(17-21-10-11-28(42-4)25(14-21)32(40)41)20(3)30-35-16-27(36-30)22-8-6-5-7-9-22/h5-14,16,20,26H,15,17,33H2,1-4H3,(H2,34,38)(H,35,36)(H,40,41)/t20-,26-/m0/s1 Key:QFNHIDANIVGXPE-FNZWTVRRSA-N

Eluxadoline, sold under the brand names Viberzi and Truberzi,^[3] is a medication taken by mouth for the treatment of diarrhea and abdominal pain in individuals with diarrhea-predominant irritable bowel syndrome (IBS-D).^[4] It was approved for use in the United States in 2015.^[5] The drug originated from Janssen Pharmaceutica and was developed by Actavis.